Alzheimer’s disease: A matter of blood–brain barrier dysfunction?
Open accessThe DOI matches its Crossref record; 198 of the 200 references it cites were found in a registry or an index.
Abstract
The blood–brain barrier (BBB) keeps neurotoxic plasma-derived components, cells, and pathogens out of the brain. An early BBB breakdown and/or dysfunction have been shown in Alzheimer’s disease (AD) before dementia, neurodegeneration and/or brain atrophy occur. However, the role of BBB breakdown in neurodegenerative disorders is still not fully understood. Here, we examine BBB breakdown in animal models frequently used to study the pathophysiology of AD, including transgenic mice expressing human amyloid-β precursor protein, presenilin 1, and tau mutations, and apolipoprotein E, the strongest genetic risk factor for AD. We discuss the role of BBB breakdown and dysfunction in neurodegenerative process, pitfalls in BBB measurements, and how targeting the BBB can influence the course of neurological disorder. Finally, we comment on future approaches and models to better define, at the cellular and molecular level, the underlying mechanisms between BBB breakdown and neurodegeneration as a basis for developing new therapies for BBB repair to control neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CAA is caused by A 𝛃 deposition in the vascular wall of small brain arteries and capillaries and develops as a result of an imbalance between A 𝛃 production and clearance, particularly faulty transvascular and perivascular clearance of A 𝛃 from the brain (318, 420, 581, 640).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, microvascular endothelial aging also disrupts the blood-brain barrier, which promotes neuroinflammation, exacerbating cognitive decline”
From Single-cell RNA sequencing identifies senescent cerebromicrovascular endothelial cells in the aged mouse brain (2020) · cites this paper as Montagne et al. 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss of claudins is associated with BBB breakdown in human neurodegenerative disorders (155, 569) and acute CNS diseases (692), as well as in animal models of these diseases (420), as discussed below.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As previously reviewed, FDG-PET reflects mainly the transport activity of GLUT1 BBB transporter (420, 569).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides FDG-PET and verapamil-PET that have been used to test functions of BBB GLUT1 transporter and activity of ABCB1 (P-gp) efflux transporter in AD and PD (420, 569), respectively”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Pericyte loss influences Alzheimer-like neurodegeneration in mice
Sagare, A. P., Bell, R. D., Zhao, Z., Ma, Q., Winkler, E. A., Ramanathan, A., & Zlokovic, B. V. (2013) · Nature Communications · doi:10.1038/ncomms3932 · Cited by 589
Self-citationRetractedSokoloff, L., Reivich, M., Kennedy, C., Rosiers, M. H. D., Patlak, C. S., Pettigrew, K. D., Sakurada, O., & Shinohara, M. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb10649.x · Cited by 6,000 · cited 6×
“…for glucose-6-phosphate isomerase and therefore cannot be converted into fructose-6-phosphate, a necessary step to enter the glycolytic pathway or Krebs cycle, as shown by multiple independent studies (Sols and Crane, 1954; Sokoloff et al., 1977; McDougal et al., 1990; Rokka et al., 2017).”
BackgroundInfluentialIliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824
Wardlaw, J. M., Smith, E. E., Biessels, G. J., Cordonnier, C., Fazekas, F., Frayne, R., Lindley, R. I., O'Brien, J. T., Barkhof, F., Benavente, O. R., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70124-8 · Cited by 5,544 · cited 13×
“…in APPSw/0 mice (at 1, 3, and 6 mo of age; Ujiie et al., 2003; Paul et al., 2007; Sagare et al., 2013) before Aβ deposition, cerebral amyloid angiopathy (CAA), and/or behavioral deficits that develop later (at 7–10, 9–12, and 6–9 mo of age, respectively; Domnitz et al., 2005; Webster et al., 2014).”
BackgroundInfluentialSleep Drives Metabolite Clearance from the Adult Brain
Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., O’Donnell, J., Christensen, D. J., Nicholson, C., Iliff, J. J., et al. (2013) · Science · doi:10.1126/science.1241224 · Cited by 5,411
Structural and functional features of central nervous system lymphatic vessels
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., Lee, K. S., et al. (2015) · Nature · doi:10.1038/nature14432 · Cited by 4,413
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · cited 1×
“Because of minimal glucose-6-phosphatase activity in the brain (Hers and De Duve, 1950; Sokoloff et al., 1977) and low 2DG-6P membrane permeability, 2DG-6P remains trapped in brain cells (Huang and Veech, 1985; Southworth et al., 2003) and is eliminated very slowly from the brain.”
BackgroundClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 2×
“, 2001; Armstrong, 2008) and imaging studies in the living human brain (Bateman et al., 2012; Benzinger et al., 2013; Fleisher et al., 2015), respectively.”
BackgroundOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“…et al., 2002; Zipser et al., 2007; Hultman et al., 2013; Zonneveld et al., 2014; Halliday et al., 2016), diminished regional BBB uptake of glucose (Ossenkoppele et al., 2013; Protas et al., 2013), and early neurovascular dysfunction (Rei- man et al., 2004; Sheline et al., 2010; Thambisetty et…”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“3157JEM Vol. 214, No. 11 (PIC ALM) protein encoded by the PIC ALM gene, a highly validated genetic risk factor for human AD (Harold et al., 2009; Lambert et al., 2009; Huang et al., 2017), accelerates Aβ deposition in APPSw/0 mice, consistent with its critical role in regulating LRP1-mediated Aβ…”
Research works printed but not linked: 2
- Hachinski, 2016, Correction. World Stroke Organization. Stroke and potentially preventable dementias proclamation: updated World Stroke Day proclamation, Stroke., 47, e37
- Holtzman, 2000, Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer’s disease model, Ann. Neurol., 47, 739, 10.1002/1531-8249(200006)47:6<739::aid-ana6>3.0.co;2-8 · doi:10.1002/1531-8249(200006)47:6<739::aid-ana6>3.0.co;2-8
Cited by
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
Self-citationBlood–brain barrier breakdown is an early biomarker of human cognitive dysfunction
Nation, D. A., Sweeney, M. D., Montagne, A., Sagare, A. P., D’Orazio, L. M., Pachicano, M., Sepehrband, F., Nelson, A. R., Buennagel, D. P., Harrington, M. G., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0297-y · Cited by 1,728
Self-citationAPOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicano, M., Joe, E., Nelson, A. R., D’Orazio, L. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2247-3 · Cited by 1,281
Self-citationZhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“363 Reduced activity and expression of the GLUT-1 transporter in the BBB suggest decreased glucose uptake and utilization by the brain, 360,363 which may further exacerbate cerebrovascular degeneration, BBB breakdown, and A β pathology in models overexpressing APP, inducing neurodegeneration and…”
BackgroundThe role of brain vasculature in neurodegenerative disorders
Sweeney, M. D., Kisler, K., Montagne, A., Toga, A. W., & Zlokovic, B. V. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0234-x · Cited by 998
Self-citationFunctional morphology of the blood–brain barrier in health and disease
Liebner, S., Dijkhuizen, R. M., Reiss, Y., Plate, K. H., Agalliu, D., & Constantin, G. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1815-1 · Cited by 872
“Glucose uptake at the BBB is disrupted in patients with mild cognitive impairment (MCI) and this may precede neurodegeneration and conversion to AD [83].”
InfluentialA human brain vascular atlas reveals diverse mediators of Alzheimer’s risk
Yang, A. C., Vest, R. T., Kern, F., Lee, D. P., Agam, M., Maat, C. A., Losada, P. M., Chen, M. B., Schaum, N., Khoury, N., et al. (2022) · Nature · doi:10.1038/s41586-021-04369-3 · Cited by 797
Vascular dysfunction—The disregarded partner of Alzheimer's disease
Sweeney, M. D., Montagne, A., Sagare, A. P., Nation, D. A., Schneider, L. S., Chui, H. C., Harrington, M. G., Pa, J., Law, M., Wang, D. J. J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.222 · Cited by 711
“Next, we focus on 2-(18)F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET), a molecular imaging biomarker for early preclinical AD and mild cognitive impairment (MCI) mentioned in the AT(N), and examine the evidence indicating that FDG-PET should also be considered a biomarker of vascular and/or blood…”
Self-citationNeuroinflammation in Alzheimer disease
Heneka, M. T., van der Flier, W. M., Jessen, F., Hoozemanns, J., Thal, D. R., Boche, D., Brosseron, F., Teunissen, C., Zetterberg, H., Jacobs, A. H., et al. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01104-7 · Cited by 638
“The role of the BBB in the removal of Aβ from the brain is well established 418 .”
Wang, C., & Holtzman, D. M. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0478-5 · Cited by 615
Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics
Petersen, M. A., Ryu, J. K., & Akassoglou, K. (2018) · Nature reviews. Neuroscience · doi:10.1038/nrn.2018.13 · Cited by 527
Physiological blood–brain transport is impaired with age by a shift in transcytosis
Yang, A. C., Stevens, M. Y., Chen, M. B., Lee, D. P., Stähli, D., Gate, D., Contrepois, K., Chen, W., Iram, T., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2453-z · Cited by 477
Yousef, H., Czupalla, C. J., Lee, D., Chen, M. B., Burke, A. N., Zera, K. A., Zandstra, J., Berber, E., Lehallier, B., Mathur, V., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0440-4 · Cited by 442
Yin, F. (2023) · The FEBS Journal · doi:10.1111/febs.16344 · Cited by 441
Merlini, M., Rafalski, V. A., Rios Coronado, P. E., Gill, T. M., Ellisman, M., Muthukumar, G., Subramanian, K. S., Ryu, J. K., Syme, C. A., Davalos, D., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.014 · Cited by 431
Role of Blood-Brain Barrier in Alzheimer’s Disease
Cai, Z., Qiao, P.-F., Wan, C.-Q., Cai, M., Zhou, N.-K., & Li, Q. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180098 · Cited by 370
“528 Yet, the role of BBB in the pathogenesis of AD is 529 still a challenge [12, 132].”
Higginbotham, L., Ping, L., Dammer, E. B., Duong, D. M., Zhou, M., Gearing, M., Hurst, C., Glass, J. D., Factor, S. A., Johnson, E. C. B., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz9360 · Cited by 367
“The BBB breakdown in AD has now been demonstrated by numerous independent postmortem human studies [48, 79].”
BackgroundHigginbotham, L., Ping, L., Dammer, E. B., Duong, D. M., Zhou, M., Gearing, M., Johnson, E. C. B., Hajjar, I., Lah, J. J., Levey, A. I., et al. (2019) · doi:10.1101/806752 · Cited by 367
Zhan, X., Stamova, B., & Sharp, F. R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00042 · Cited by 351
“In addition, BBB breakdown has been demonstrated in humans with mild cognitive impairment (MCI) and early AD before brain atrophy and dementia (Montagne et al., 2017).”
BackgroundSasannejad, C., Ely, E. W., & Lahiri, S. (2019) · Critical Care · doi:10.1186/s13054-019-2626-z · Cited by 326
Preventing dementia by preventing stroke: The Berlin Manifesto
Hachinski, V., Einhäupl, K., Ganten, D., Alladi, S., Brayne, C., Stephan, B. C. M., Sweeney, M. D., Zlokovic, B., Iturria‐Medina, Y., Iadecola, C., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.06.001 · Cited by 313
“In particular, vascular dysregulation appears to be one of the first signs in the temporal evolution of AD [15], which gradually unfolds in the brain over one or two decades before the deposits of amyloid and tau start to become visible with molecular PET imaging [98].”
BackgroundHealthy aging and the blood–brain barrier
Banks, W. A., Reed, M. J., Logsdon, A. F., Rhea, E. M., & Erickson, M. A. (2021) · Nature Aging · doi:10.1038/s43587-021-00043-5 · Cited by 292
Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement
Stanciu, G. D., Luca, A., Rusu, R. N., Bild, V., Beschea Chiriac, S. I., Solcan, C., Bild, W., & Ababei, D. C. (2019) · Biomolecules · doi:10.3390/biom10010040 · Cited by 297
Blood-brain barrier–penetrating siRNA nanomedicine for Alzheimer’s disease therapy
Zhou, Y., Zhu, F., Liu, Y., Zheng, M., Wang, Y., Zhang, D., Anraku, Y., Zou, Y., Li, J., Wu, H., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc7031 · Cited by 300
Factors influencing the blood-brain barrier permeability
Zhao, Y., Gan, L., Ren, L., Lin, Y., Ma, C., & Lin, X. (2022) · Brain Research · doi:10.1016/j.brainres.2022.147937 · Cited by 291
Restoring Wnt/β-catenin signaling is a promising therapeutic strategy for Alzheimer’s disease
Jia, L., Piña-Crespo, J., & Li, Y. (2019) · Molecular Brain · doi:10.1186/s13041-019-0525-5 · Cited by 288
Ma, Q., Zhao, Z., Sagare, A. P., Wu, Y., Wang, M., Owens, N. C., Verghese, P. B., Herz, J., Holtzman, D. M., & Zlokovic, B. V. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0286-0 · Cited by 281
Self-citationBlood–Brain Barrier Dysfunction in a 3D In Vitro Model of Alzheimer's Disease
Shin, Y., Choi, S. H., Kim, E., Bylykbashi, E., Kim, J. A., Chung, S., Kim, D. Y., Kamm, R. D., & Tanzi, R. E. (2019) · Advanced Science · doi:10.1002/advs.201900962 · Cited by 274
Bridging barriers: a comparative look at the blood–brain barrier across organisms
O'Brown, N. M., Pfau, S. J., & Gu, C. (2018) · Genes & Development · doi:10.1101/gad.309823.117 · Cited by 263
“2017) but also demarcating differences between disease pathophysiologies inmurinemodels of Alzheimer’s disease (Montagne et al. 2017) and stroke (Knowland et al.”
BackgroundTargeting Neuroinflammation to Treat Alzheimer’s Disease
Ardura-Fabregat, A., Boddeke, E. W. G. M., Boza-Serrano, A., Brioschi, S., Castro-Gomez, S., Ceyzériat, K., Dansokho, C., Dierkes, T., Gelders, G., Heneka, M. T., et al. (2017) · CNS Drugs · doi:10.1007/s40263-017-0483-3 · Cited by 233
In Vitro Models of the Blood-Brain Barrier
Neuhaus, W. (2020) · Handbook of Experimental Pharmacology · doi:10.1007/164_2020_370 · Cited by 236
Activation of Wnt/β-catenin pathway mitigates blood–brain barrier dysfunction in Alzheimer’s disease
Wang, Q., Huang, X., Su, Y., Yin, G., Wang, S., Yu, B., Li, H., Qi, J., Chen, H., Zeng, W., et al. (2022) · Brain · doi:10.1093/brain/awac236 · Cited by 210
“These findings are consistent with the pathological changes in BECs in previous studies.(10,11,47,48)”
ResultIntracellular transport and regulation of transcytosis across the blood–brain barrier
Villaseñor, R., Lampe, J., Schwaninger, M., & Collin, L. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2982-x · Cited by 209
Increase in blood–brain barrier leakage in healthy, older adults
Verheggen, I. C. M., de Jong, J. J. A., van Boxtel, M. P. J., Gronenschild, E. H. B. M., Palm, W. M., Postma, A. A., Jansen, J. F. A., Verhey, F. R. J., & Backes, W. H. (2020) · GeroScience · doi:10.1007/s11357-020-00211-2 · Cited by 205
“The endothelium contains specialized transport systems that allow nutrients to move from the blood to the brain, while waste products are removed in the opposite direction (Montagne et al. 2017; Zhao et al. 2015).”
Gehrke, N., & Schattenberg, J. M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.020 · Cited by 209
Blood–Brain Barrier Breakdown in Alzheimer’s Disease: Mechanisms and Targeted Strategies
Alkhalifa, A. E., Al-Ghraiybah, N. F., Odum, J., Shunnarah, J. G., Austin, N., & Kaddoumi, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216288 · Cited by 212
“This change in the BBB’s permeability is implicated in the pathophysiology of neurodegenerative diseases, including AD, by facilitating neuroinflammation through unregulated protein entry [46,47].”
BackgroundChen, T., Dai, Y., Hu, C., Lin, Z., Wang, S., Yang, J., Zeng, L., Li, S., & Li, W. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00557-1 · Cited by 189
“TJs, composed of claudins, occludin, junctional adhesion molecules (JAMs), and the zonula occludin (ZO) family, are believed to regulate vascular paracellular transport by forming a high-resistance electrical barrier [17].”
BackgroundRelationship Between Amyloid-β Deposition and Blood–Brain Barrier Dysfunction in Alzheimer’s Disease
Wang, D., Chen, F., Han, Z., Yin, Z., Ge, X., & Lei, P. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.695479 · Cited by 197
Hladky, S. B., & Barrand, M. A. (2018) · Fluids and Barriers of the CNS · doi:10.1186/s12987-018-0113-6 · Cited by 206
Kiss, T., Nyúl-Tóth, Á., Balasubramanian, P., Tarantini, S., Ahire, C., DelFavero, J., Yabluchanskiy, A., Csipo, T., Farkas, E., Wiley, G., et al. (2020) · GeroScience · doi:10.1007/s11357-020-00177-1 · Cited by 203
“There is strong evidence that aging-induced dysregulation of microvascular endothelial function and phenotype critically contributes to the pathogenesis of both vascular cognitive impairment (VCI) and Alzheimer’s disease (AD) (Tarantini et al. 2017a; Csiszar et al. 2017; Csipo et al. 2018; Csipo et al. 2019a; Csipo et…”
BackgroundInfluentialAge-Associated Changes in the Immune System and Blood–Brain Barrier Functions
Erickson, M. A., & Banks, W. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071632 · Cited by 198
Yamazaki, Y., Shinohara, M., Shinohara, M., Yamazaki, A., Murray, M. E., Liesinger, A. M., Heckman, M. G., Lesser, E. R., Parisi, J. E., Petersen, R. C., et al. (2019) · Brain · doi:10.1093/brain/awz011 · Cited by 202
Cheng, Y., Tian, D.-Y., & Wang, Y.-J. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00195-1 · Cited by 190
Endothelium-Macrophage Crosstalk Mediates Blood-Brain Barrier Dysfunction in Hypertension
Santisteban, M. M., Ahn, S. J., Lane, D., Faraco, G., Garcia-Bonilla, L., Racchumi, G., Poon, C., Schaeffer, S., Segarra, S. G., Körbelin, J., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15581 · Cited by 188
“Interestingly, in animal models of neurodegeneration the BBB dysfunction precedes cognitive dysfunction, also attesting to its potential pathogenic role.(63,64) Recent data suggest a similar temporal relationship in patients with early cognitive dysfunction at risk for Alzheimer’s disease.”
BackgroundSingle-nucleus multiregion transcriptomic analysis of brain vasculature in Alzheimer’s disease
Sun, N., Akay, L. A., Murdock, M. H., Park, Y., Galiana-Melendez, F., Bubnys, A., Galani, K., Mathys, H., Jiang, X., Ng, A. P., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01334-3 · Cited by 164
Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease
Williams, T., Borchelt, D. R., & Chakrabarty, P. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-0358-9 · Cited by 171
Gouveia-Freitas, K., & Bastos-Leite, A. J. (2021) · Neuroradiology · doi:10.1007/s00234-021-02718-7 · Cited by 159
“Lack of integrity of the vascular wall in association with the occurrence of microbleeds, CAA and enlarged PVS often occurs in the preclinical stages of AD, preceding substantial brain volume loss [37].”
BackgroundKiss, T., Nyúl-Tóth, Á., Balasubramanian, P., Tarantini, S., Ahire, C., Yabluchanskiy, A., Csipo, T., Farkas, E., Wren, J. D., Garman, L., et al. (2020) · GeroScience · doi:10.1007/s11357-020-00165-5 · Cited by 163
“In addition, cells constituting the NVU form andmaintain the blood-brain barrier (Zlokovic 2010, 2011; Montagne et al. 2017; Sweeney et al. 2018, 2019a; Zlokovic 2008), regulate transport processes and waste removal, deposit the extracellular matrix, control the structural remodeling of the cerebral microcirculation (…”
BackgroundExercise suppresses neuroinflammation for alleviating Alzheimer’s disease
Wang, M., Zhang, H., Liang, J., Huang, J., & Chen, N. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02753-6 · Cited by 161
“Previous studies have confirmed that BBB is closely related to the occurrence and development of AD and is also a key point in preventing and treating AD [223].”
BackgroundThe Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer’s Disease
Kloske, C. M., & Wilcock, D. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00754 · Cited by 152
Pfau, S. J., Langen, U. H., Fisher, T. M., Prakash, I., Nagpurwala, F., Lozoya, R., Lee, W.-C. A., Wu, Z., & Gu, C. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01743-y · Cited by 153
Neurovascular Interactions in the Nervous System
Segarra, M., Aburto, M. R., Hefendehl, J. K., & Acker‐Palmer, A. (2019) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100818-125142 · Cited by 144
Alajangi, H. K., Kaur, M., Sharma, A., Rana, S., Thakur, S., Chatterjee, M., Singla, N., Jaiswal, P. K., Singh, G., & Barnwal, R. P. (2022) · Molecular Brain · doi:10.1186/s13041-022-00937-4 · Cited by 146
“Mutations in human PSEN1 have been shown to promote the breakdown of BBB and cerebrovascular dysfunction [98].”
Bacteroidetes Neurotoxins and Inflammatory Neurodegeneration
Zhao, Y., & Lukiw, W. J. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1015-y · Cited by 143
High Mobility Group Box-1 and Blood–Brain Barrier Disruption
Nishibori, M., Wang, D., Ousaka, D., & Wake, H. (2020) · Cells · doi:10.3390/cells9122650 · Cited by 138
“In a mouse model of Alzheimer’s disease, a similar pattern of BBB breakdown was observed before the manifestation of impairment of cognitive functions [128].”
BackgroundPathological changes within the cerebral vasculature in Alzheimer’s disease: New perspectives
Fisher, R. A., Miners, J. S., & Love, S. (2022) · Brain Pathology · doi:10.1111/bpa.13061 · Cited by 138
Liu, C.-Y., Yang, Y., Ju, W.-N., Wang, X., & Zhang, H.-L. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00193 · Cited by 131
Neuropathogenesis-on-chips for neurodegenerative diseases
Amartumur, S., Nguyen, H. M., Huynh, T., Kim, T. S., Woo, R., Oh, E., Kim, K. K., Lee, L. P., & Heo, C. (2024) · Nature Communications · doi:10.1038/s41467-024-46554-8 · Cited by 140
Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance
Nehra, G., Bauer, B., & Hartz, A. M. S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108119 · Cited by 127
Al‐Majdoub, Z. M., Feteisi, H. A., Achour, B., Warwood, S., Neuhoff, S., Rostami‐Hodjegan, A., & Barber, J. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01189 · Cited by 127
Revisiting the blood-brain barrier: A hard nut to crack in the transportation of drug molecules
Harilal, S., Jose, J., Parambi, D. G. T., Kumar, R., Unnikrishnan, M. K., Uddin, M. S., Mathew, G. E., Pratap, R., Marathakam, A., & Mathew, B. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.03.018 · Cited by 131
Zhao, L., Li, Z., Vong, J. S. L., Chen, X., Lai, H. M., Yan, L. Y. C., Huang, J., Sy, S. K. H., Tian, X. Y., Huang, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18249-3 · Cited by 141
Is Alzheimer’s Disease a Liver Disease of the Brain?
Bassendine, M. F., Taylor-Robinson, S. D., Fertleman, M., Khan, M., & Neely, D. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-190848 · Cited by 124
“The BBB keeps neurotoxic plasma derived components out of the central nervous system, but recent studies suggest an early BBB breakdown in AD [19].”
BackgroundContributions of Aging to Cerebral Small Vessel Disease
Silva, T. M. D., & Faraci, F. M. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021119-034338 · Cited by 133
“CADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy useful reviews on related subjects such as cerebrovascular changes during Alzheimer’s disease (8, 9), we do not emphasize that subject or studies based on surgically or pharmacologically induced reductions in cerebral b…”
BackgroundXiao, M., Xiao, Z. J., Yang, B., Lan, Z., & Fang, F. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00764 · Cited by 135
Role of Vitamin D Deficiency in the Pathogenesis of Cardiovascular and Cerebrovascular Diseases
Pál, É., Ungvari, Z. I., Benyó, Z., & Várbíró, S. (2023) · Nutrients · doi:10.3390/nu15020334 · Cited by 121
Chen, Y., He, Y., Han, J., Wei, W., & Chen, F. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1258640 · Cited by 116
“Pathological evidence of cerebrovascular and BBB dysfunction in AD transgenic mouse models has also been frequently reported (Montagne et al., 2017).”
BackgroundCOVID-19 and Alzheimer’s Disease
Ciaccio, M., Sasso, B. L., Scazzone, C., Gambino, C. M., Ciaccio, A. M., Bivona, G., Piccoli, T., Giglio, R. V., & Agnello, L. (2021) · Brain Sciences · doi:10.3390/brainsci11030305 · Cited by 124
In vitro Models of the Blood–Brain Barrier: Tools in Translational Medicine
Williams-Medina, A. R., Deblock, M. C., & Janigro, D. (2021) · Frontiers in Medical Technology · doi:10.3389/fmedt.2020.623950 · Cited by 120
“It has been shown that the astrocytic ApoE ε4 isoform poses the major genetic risk toward developing AD, and recent evidence has shown that lack of ApoE disrupts the BBB (102, 125, 126).”
BackgroundChoroid plexus genes for CSF production and brain homeostasis are altered in Alzheimer’s disease
Kant, S., Stopa, E. G., Johanson, C. E., Baird, A., & Silverberg, G. D. (2018) · Fluids and Barriers of the CNS · doi:10.1186/s12987-018-0120-7 · Cited by 126
Kiss, T., Giles, C. B., Tarantini, S., Yabluchanskiy, A., Balasubramanian, P., Gautam, T., Csípő, T., Nyúl‐Tóth, Á., Lipécz, Á., Szabó, C., et al. (2019) · GeroScience · doi:10.1007/s11357-019-00095-x · Cited by 121
An Integrated View on Vascular Dysfunction in Alzheimer’s Disease
Klohs, J. (2019) · Neurodegenerative Diseases · doi:10.1159/000505625 · Cited by 111
Endothelial Mitochondrial Dysfunction in Cerebral Amyloid Angiopathy and Alzheimer’s Disease
Parodi‐Rullán, R. M., Sone, J. Y., & Fossati, S. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190357 · Cited by 117
“Transgenic murine models of CAA and AD have further corroborated such BBB dysfunction [84].”
Hoogmartens, J., Cacace, R., & Broeckhoven, C. V. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12155 · Cited by 136
Alzheimer's disease pathophysiology in the Retina
Gaire, B. P., Koronyo, Y., Fuchs, D.-T. S., Shi, H., Rentsendorj, A., Danziger, R., Vit, J., Mirzaei, N., Doustar, J., Sheyn, J., et al. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101273 · Cited by 110
The complement cascade in Alzheimer’s disease: a systematic review and meta-analysis
Krance, S. H., Wu, C., Zou, Y. Z., Mao, H., Toufighi, S., He, X., Pakosh, M. T., & Swardfager, W. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0536-8 · Cited by 102
Shen, Y., Hua, L., Yeh, C., Shen, L., Ying, M., Zhang, Z., Liu, G., Li, S., Chen, S., Chen, X., et al. (2020) · Theranostics · doi:10.7150/thno.44152 · Cited by 103
“, has gained much attention for a potential therapeutic strategy for AD therapy [21].”
BackgroundRole of pyroptosis in the pathogenesis of various neurological diseases
Oladapo, A., Jackson, T., Menolascino, J., & Periyasamy, P. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.02.001 · Cited by 103
Dithmer, S., Blasig, I. E., Fraser, P. A., Qin, Z., & Haseloff, R. F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115601 · Cited by 107
“Leakage of the barrier is observed in the early stages of some brain diseases and might even contribute to disease progression [315,316].”
BackgroundP‐glycoprotein: a role in the export of amyloid‐β in Alzheimer's disease?
Chai, A. B., Leung, G. K. F., Callaghan, R., & Gelissen, I. C. (2019) · FEBS Journal · doi:10.1111/febs.15148 · Cited by 101
The Role of Neurovascular System in Neurodegenerative Diseases
Ahmad, A., Patel, V., Xiao, J., & Khan, M. M. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02023-z · Cited by 105
“Impaired glymphatic system [61–63] Reduced tight junction proteins [20, 46]”
BackgroundHarnessing endophenotypes and network medicine for Alzheimer's drug repurposing
Fang, J., Pieper, A. A., Nussinov, R., Lee, G., Bekris, L. M., Leverenz, J. B., Cummings, J. L., & Cheng, F. (2020) · Medicinal Research Reviews · doi:10.1002/med.21709 · Cited by 102
Terminal complement pathway activation drives synaptic loss in Alzheimer’s disease models
Carpanini, S. M., Torvell, M., Bevan, R. J., Byrne, R. A. J., Daskoulidou, N., Saito, T., Saido, T. C., Taylor, P. R., Hughes, T. R., Zelek, W. M., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01404-w · Cited by 95
Matrix Metalloproteinases as New Targets in Alzheimer’s Disease: Opportunities and Challenges
Zipfel, P., Rochais, C., Baranger, K., Rivera, S., & Dallemagne, P. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00352 · Cited by 94
Obesity as a Risk Factor for Alzheimer’s Disease: Implication of Leptin and Glutamate
Lloret, A., Monllor, P., Esteve, D., Cervera‐Ferri, A., & Lloret, M.-Á. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00508 · Cited by 98
“Moreover, Aβ causes an increase of glutamate levels and this leads to a dysfunction in extrasynaptic NMDAR, a decrease in LTP and mitochondrial alterations.”
BackgroundInfluentialAstrocytes in the regulation of cerebrovascular functions
Cohen‐Salmon, M., Slaoui, L., Mazaré, N., Gilbert, A., Oudart, M., Alvear‐Perez, R., Elorza‐Vidal, X., Chever, O., & Boulay, A. (2021) · Glia · doi:10.1002/glia.23924 · Cited by 93
The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer’s disease
Su, Q., Guo, J.-H., Zhang, Y.-L., Wang, J., & Zhang, Z.-N. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335829 · Cited by 91
“The physical barrier structures in endothelial cells are essential for the regulation of many cellular functions and play a vital role in maintaining BBB permeability and brain parenchyma homeostasis (Montagne et al., 2017).”
BackgroundShao, X., Jann, K., Ma, S. J., Yan, L., Montagne, A., Ringman, J. M., Zloković, B. V., & Wang, D. J. J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.571480 · Cited by 91
“, 2019), in contrast to several other studies in rodentmodels of AD (Montagne et al., 2017).”
ResultSelf-citationIn vivo methods for imaging blood–brain barrier function and dysfunction
Harris, W. J., Asselin, M., Hinz, R., Parkes, L. M., Allan, S. M., Schießl, I., Boutin, H., & Dickie, B. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05997-1 · Cited by 98
Khan, A. M., Korzeniowska, B., Gorshkov, V., Tahir, M., Schrøder, H. D., Skytte, L., Rasmussen, K. L., Khandige, S., Møller‐Jensen, J., & Kjeldsen, F. (2019) · Nanotoxicology · doi:10.1080/17435390.2018.1540728 · Cited by 91
Neural stem cell therapy for neurovascular injury in Alzheimer's disease
Boese, A. C., Hamblin, M. H., & Lee, J. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113112 · Cited by 92
Blood–brain barrier endothelial cells in neurodegenerative diseases: Signals from the “barrier”
Yuan, Y., Sun, J., Dong, Q., & Cui, M. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1047778 · Cited by 92
“The discussion about the role of BECs tends to focus on the influx of circulating pathogens or neurotoxic materials through the broken BBB rather than the actions and conditions of BECs (Montagne et al., 2017; Sweeney et al., 2018).”
BackgroundNeurovascular dysfunction in glaucoma
Alarcón-Martínez, L., Shiga, Y., Villafranca‐Baughman, D., Vargas, J. L. C., Vidal-Paredes, I. A., Quintero, H., Fortune, B. A., Danesh-Meyer, H. V., & Polo, A. D. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2023.101217 · Cited by 94
“The microenvironment in the retina and optic nerve is tightly regulated and kept separate from the systemic circulation by the BRB and the BBB, which prevent the entry of cytotoxic plasma components, blood cells, and pathogens (Montagne et al., 2017).”
BackgroundOsaid, Z., Haider, M. A., Hamoudi, R., & Harati, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115635 · Cited by 93
“Dysfunctional BBB dynamics have been implicated in the pathogenesis of AD [165].”
BackgroundOikari, L. E., Pandit, R., Stewart, R., Cuní‐López, C., Quek, H., Sutharsan, R., Rantanen, L. M., Oksanen, M., Lehtonen, Š., de Boer, C. M., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.03.011 · Cited by 95
Imaging the role of blood–brain barrier disruption in normal cognitive ageing
Verheggen, I. C. M., de Jong, J. J. A., van Boxtel, M. P. J., Postma, A. A., Jansen, J. F. A., Verhey, F. R. J., & Backes, W. H. (2020) · GeroScience · doi:10.1007/s11357-020-00282-1 · Cited by 89
Could Alzheimer’s Disease Originate in the Periphery and If So How So?
Morris, G., Berk, M., Maes, M. H. J., & Puri, B. K. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1092-y · Cited by 90
Morofuji, Y., & Nakagawa, S. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200224112534 · Cited by 87
Common Peripheral Immunity Mechanisms in Multiple Sclerosis and Alzheimer's Disease
Rossi, B., Santos-Lima, B., Terrabuio, E., Zenaro, E., & Constantin, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.639369 · Cited by 91
“Moreover, reducing BBB breakdown that characterizes several neurodegenerative disorders, including MS and AD, could be considered as another common possible therapeutic strategy in reducing not only the influx of various neurotoxic agents, but also the recruitment of immune cells into the CNS (220, 221).”
Background
Metadata
- Authors
- Montagne, A., Zhao, Z., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, Los Angeles, CA 1
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2017-10-23
- Volume
- 214
- Issue
- 11
- Pages
- 3151-3169
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC5679168
- OpenAlex
- W2766949297
- Cited by
- 672
- References
- 200
- Citations by year
- 2026: 54 · 2025: 56 · 2024: 93 · 2023: 82 · 2022: 82 · 2021: 90 · 2020: 91 · 2019: 76 · 2018: 46 · 2017: 2
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (R01AG023084, R01NS090904, R01NS034467, R01AG039452, 5P01AG052350)
- Cure for Alzheimer’s Fund
- Alzheimer’s Association
- Fondation Leducq (16 CVD 05)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Alzheimer's disease, blood-brain barrier dysfunction, blood-brain barrier disruption, neurodegeneration, amyloid precursor protein, presenilin 1, tau mutations, apolipoprotein E, transgenic mouse model, BBB repair
- MeSH terms
- Alzheimer Disease, Animals, Blood-Brain Barrier, Disease Models, Animal, Humans, Mice, Transgenic, Mutation, Amyloid beta-Protein Precursor, tau Proteins, Presenilin-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.